NOTE: Where it is feasible, a syllabus (headnote) will be released,
as is being done in connection with this case, at the time the
opinion is issued.  The syllabus constitutes no part of the opinion
of the Court but has been prepared by the Reporter of Decisions for
the convenience of the reader.
See United States v. Detroit Lumber Co., 200 U. S. 321, 337.
SUPREME COURT OF THE UNITED STATES
Syllabus
DAUBERT et ux., individually and as guardians
and litem for DAUBERT, et al. v. MERRELL
DOW PHARMACEUTICALS, INC.
certiorari to the united states court of appeals for
the ninth circuit
No. 92-102.   Argued March 30, 1993-Decided June 28, 1993
Petitioners, two minor children and their parents, alleged in
their suit against respondent that the children's serious birth
defects had been caused by the mothers' prenatal ingestion of
Bendectin, a prescription drug marketed by respondent.  The
District Court granted respondent summary judgment based on a
well-credentialed expert's affidavit concluding, upon reviewing
the extensive published scientific literature on the subject, that
maternal use of Bendectin has not been shown to be a risk factor
for human birth defects.
---
---------------